Full Text Journal Articles in
Journal J. Natl. Cancer Inst.

Advertisement

Find full text journal articles






Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: the CVT Trial.

Sabrina H Tsang, Joshua N Sampson, John Schussler, Carolina Porras, Sarah Wagner, Joseph Boland, Bernal Cortes, Douglas R Lowy, John T Schiller, Mark Schiffman, Troy J Kemp, Ana Cecilia Rodriguez, Wim Quint, Mitchell H Gail, Ligia A Pinto, Paula Gonzalez, Allan Hildesheim, Aimée R Kreimer, Rolando Herrero, ,

BACKGROUND:The Costa Rica HPV Vaccine Trial (CVT) has documented cross-protection of the bivalent HPV vaccine against HPV31/33/45 up to seven years after vaccination, even with one dose of the vaccine. However, the durability of such protection remains unknown. Here, we evaluate different schedules of the vaccine's efficacy against HPV31/33/45 out ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort.

Chunling Hu, Eric C Polley, Siddhartha Yadav, Jenna Lilyquist, Hermela Shimelis, Jie Na, Steven N Hart, David E Goldgar, Swati Shah, Tina Pesaran, Jill S Dolinsky, Holly LaDuca, Fergus J Couch,

BACKGROUND:The germline cancer predisposition genes associated with increased risk of each clinical subtype of breast cancer, defined by estrogen receptor (ER), progesterone receptor (PR), and HER2, are not well defined. METHODS:A total of 54,555 invasive breast cancer patients with 56,480 breast tumors were subjected to clinical hereditary cancer multigene panel ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Evaluating Treatment Tolerability in Cancer Clinical Trials using the Toxicity Index.

Gillian Gresham, Márcio A Diniz, Zahra S Razaee, Michael Luu, Sungjin Kim, Ron D Hays, Steven Piantadosi, Mourad Tighiouart, Greg Yothers, Patricia A Ganz, André Rogatko,

BACKGROUND:The National Cancer Institute Moonshot℠ research initiative calls for improvements in the analysis and reporting of treatment toxicity to advise key stakeholders on treatment tolerability and inform regulatory and clinical decision-making. This study illustrates alternative approaches to toxicity evaluation using the National Surgical Adjuvant Breast and Bowel Project (NSABP-R04) clinical ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



The Value of All-Cause Mortality as a Metric for Assessing Breast Cancer Screening.

Martin J Yaffe, James G Mainprize,

While screening mammography has been demonstrated to contribute to reducing mortality due to breast cancer, some have suggested that reduced all-cause mortality should constitute the burden of proof for effectiveness. Using a microsimulation model of the development, detection and treatment of breast cancer it is straightforward to demonstrate that this ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Emily Z Keung, Jeffrey E Gershenwald,

The incidence of melanoma in the United States has been increasing over the past several decades. Prognosis largely depends on disease stage, with 5-year melanoma-specific survival ranging from as high as 99% in patients with stage I disease to less than 10% for some patients with stage IV (distant metastatic) ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Conditional Survival, Cause-specific Mortality, Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation.

F Lennie Wong, Jennifer Berano, Liezl Atencio, Tracey Stiller, Heeyoung Kim, Dayana Chanson, Stephen J Forman, Ryotaro Nakamura, Saro H Armenian,

BACKGROUND:Long-term mortality after hematopoietic cell transplantation (HCT) is conventionally calculated from the time of HCT, ignoring temporal changes in survivors' mortality risks. Conditional survival rates, accounting for time already survived, are relevant for optimal delivery of survivorship care, but have not been widely quantified. We estimated conditional survival by elapsed ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Disparities of national lung cancer screening guidelines in the U.S. population.

Summer S Han, Eric Chow, Kevin Ten Haaf, Iakovos Toumazis, Pianpian Cao, Mehrad Bastani, Martin Tammemagi, Jihyoun Jeon, Eric Feuer, Rafael Meza, Sylvia Plevritis,

BACKGROUND:Current U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelines are based on smoking history and age (55-80 y). These guidelines may miss those at higher risk, even at lower exposures of smoking or younger ages, due to other risk factors such as race, family history or comorbidity. In ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Young-Onset Colon Cancer and Recurrence Risk By Gene Expression.

George J Chang, Y Nancy Y You, Christy A Russell, Marni B Tierno, Michelle Turner, John P Bennett, Anna Lau, Howard S Hochster,

The incidence and mortality from colorectal cancer in younger adults (<55 years) is increasing. We reviewed the complete database of a gene-expression test, Oncotype DX Colon Recurrence Score® test, to determine age-related differences in Recurrence Score® (RS) and single-gene results (7 cancer-related of the 12-gene assay). We included 20,478 Stage ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



The Evolving Status of Radiomics.

Philip O Alderson, Ronald M Summers,

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



The Role of Neoadjuvant Chemotherapy in Patients with Resectable Malignant Pleural Mesothelioma - An Institutional and National Analysis.

Soraya L Voigt, Vignesh Raman, Oliver K Jawitz, Muath Bishawi, Chi-Fu Jeffrey Yang, Betty C Tong, Thomas D'Amico, David H Harpole,

BACKGROUND:There is no standard of care with respect to the use of neoadjuvant chemotherapy (NAC) in resectable malignant pleural mesothelioma (MPM). We performed an intention-to-treat analysis with data from a single institution and the National Cancer Database (NCDB) to identify whether the use of NAC impacts survival in resectable MPM. ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017.

Jared C Foster, Boris Freidlin, Charles A Kunos, Edward L Korn,

Designing and interpreting single-arm phase II trials of combinations of agents is challenging because it can be difficult, based on historical data, to identify levels of activity for which the combination would be worth pursuing. We identified Cancer Therapy Evaluation Program single-arm combination trials that were activated in 2008-2017 and ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):128-135]

Cited: 0 times

View full text PDF listing >>



Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program.

Anna M Chiarelli, Kristina M Blackmore, Derek Muradali, Susan J Done, Vicky Majpruz, Ashini Weerasinghe, Lucia Mirea, Andrea Eisen, Linda Rabeneck, Ellen Warner,

BACKGROUND:The Ontario Breast Screening Program expanded in July 2011 to screen high-risk women age 30-69 years with annual magnetic resonance imaging (MRI) and digital mammography. This study examined the benefits of screening with mammography and MRI by age and risk criteria. METHODS:This prospective cohort study included 8782 women age 30-69 years ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):136-144]

Cited: 0 times

View full text PDF listing >>



Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.

Angela Lamarca, Paul Ross, Harpreet S Wasan, Richard A Hubner, Mairéad G McNamara, Andre Lopes, Prakash Manoharan, Daniel Palmer, John Bridgewater, Juan W Valle,

BACKGROUND:The incidence of intrahepatic cholangiocarcinoma (iCCA) is increasing. The aim of the study was to provide reference survival data for patients with advanced iCCA treated with first-line cisplatin-gemcitabine chemotherapy (current standard of care). METHODS:Individual data from patients with iCCA recruited into the prospective, random assignment Advanced Biliary Tract Cancer (ABC)-01, ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):200-210]

Cited: 1 time

View full text PDF listing >>



Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.

Laurent Dercle, Lin Lu, Lawrence H Schwartz, Min Qian, Sabine Tejpar, Peter Eggleton, Binsheng Zhao, Hubert Piessevaux,

BACKGROUND:To forecast survival and enhance treatment decisions for patients with colorectal cancer liver metastases (mCRC) by using on-treatment radiomics signature to predict tumor sensitiveness to FOLFIRI±cetuximab. METHODS:We retrospectively analyzed 667 mCRC patients treated with FOLFIRI alone [F] or in combination with cetuximab [FC]. CT quality was classified as high (HQ) ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



International trends in the incidence of cancer among adolescents and young adults.

Sumit Gupta, Andrew Harper, Yibing Ruan, Ronald Barr, A Lindsay Frazier, Jacques Ferlay, Eva Steliarova-Foucher, Miranda M Fidler-Benaoudia,

BACKGROUND:Although adolescent and young adult (AYA) cancers represent a unique spectrum of malignancies, epidemiologic studies of cancer incidence often group AYAs together with younger or older populations, obscuring patterns specific to this population. METHODS:We examined AYA cancer incidence trends in 41 countries over a 15-year period using the CI5plus database. ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Response to Habel and Buist.

Marc D Ryser, E Shelley Hwang,

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):216-217]

Cited: 0 times

View full text PDF listing >>



Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.

Angela Mariotto, Jinani Jayasekerea, Valentina Petkov, Clyde B Schechter, Lindsey Enewold, Kathy J Helzlsouer, Eric J Feuer, Jeanne S Mandelblatt,

BACKGROUND:TAILORx demonstrated that women with node-negative, hormone receptor-positive, HER2-negative breast cancers and Oncotype DX recurrence scores (RS) of 0-25 had similar 9-year outcomes with endocrine vs chemo-endocrine therapy; evidence for women aged 50 years and younger and RS 16-25 was less clear. We estimated how expected changes in practice following ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):154-160]

Cited: 1 time

View full text PDF listing >>



Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial.

You-Lin Qiao, Ting Wu, Rong-Cheng Li, Yue-Mei Hu, Li-Hui Wei, Chang-Gui Li, Wen Chen, Shou-Jie Huang, Fang-Hui Zhao, Ming-Qiang Li, Qin-Jing Pan, Xun Zhang, Qing Li, Ying Hong, Chao Zhao, Wen-Hua Zhang, Yan-Ping Li, Kai Chu, Mei Li, Yun-Fei Jiang, Juan Li, Hui Zhao, Zhi-Jie Lin, Xue-Lian Cui, Wen-Yu Liu, Cai-Hong Li, Dong-Ping Guo, Li-Dong Ke, Xin Wu, Jie Tang, Guo-Qi Gao, Ba-Yi Li, Bin Zhao, Feng-Xian Zheng, Cui-Hong Dai, Meng Guo, Jun Zhao, Ying-Ying Su, Jun-Zhi Wang, Feng-Cai Zhu, Shao-Wei Li, Hui-Rong Pan, Yi-Min Li, Jun Zhang, Ning-Shao Xia,

BACKGROUND:The high cost and insufficient supply of human papillomavirus (HPV) vaccines have slowed the pace of controlling cervical cancer. A phase III clinical trial was conducted to evaluate the efficacy, safety, and immunogenicity of a novel Escherichia coli-produced bivalent HPV-16/18 vaccine. METHODS:A multicenter, randomized, double-blind trial started on November 22, ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):145-153]

Cited: 0 times

View full text PDF listing >>



Potential Effect of Immunotherapy Agents on Cognitive Function in Cancer Patients.

Florence Joly, Hélène Castel, Laure Tron, Marie Lange, Janette Vardy,

A paradigm shift is occurring in cancer therapy, where instead of targeting tumor cells, immunotherapy agents (IA) target the immune system to overcome cancer tolerance and to stimulate an antitumor immune response. IA using immune checkpoint inhibitors (CPI) or chimeric antigen receptor T-cells have emerged as the most encouraging approaches ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):123-127]

Cited: 0 times

View full text PDF listing >>



Breast Cancer Screening in High-Risk Women: Is MRI Alone Enough?

Carolina Rossi Saccarelli, Almir G V Bitencourt, Elizabeth A Morris,

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):121-122]

Cited: 0 times

View full text PDF listing >>



Re: Cancer Outcomes in DCIS Patients Without Locoregional Treatment.

Laurel A Habel, Diana S M Buist,

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):214-215]

Cited: 0 times

View full text PDF listing >>



Insulin Resistance and Cancer-Specific and All-Cause Mortality in Postmenopausal Women: The Women's Health Initiative.

Kathy Pan, Rebecca A Nelson, Jean Wactawski-Wende, Delphine J Lee, JoAnn E Manson, Aaron K Aragaki, Joanne E Mortimer, Lawrence S Phillips, Thomas Rohan, Gloria Y F Ho, Nazmus Saquib, Aladdin H Shadyab, Rami Nassir, Jinnie J Rhee, Arti Hurria, Rowan T Chlebowski,

BACKGROUND:Insulin resistance has been proposed as a mediator of the increased cancer incidence and mortality associated with obesity. However, prior studies included limited cancer deaths and had inconsistent findings. Therefore, we evaluated insulin resistance and cancer-specific and all-cause mortality in postmenopausal women participating in the Women's Health Initiative (WHI). METHODS:Eligible ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):170-178]

Cited: 0 times

View full text PDF listing >>



Sex-Based Disparities Among Cancer Clinical Trial Participants.

Ethan B Ludmir, C David Fuller, Shalini Moningi, Walker Mainwaring, Timothy A Lin, Austin B Miller, Amit Jethanandani, Andres F Espinoza, Vivek Verma, Benjamin D Smith, Grace L Smith, Noam A VanderWalde, Emma B Holliday, B Ashleigh Guadagnolo, Thomas E Stinchcombe, Reshma Jagsi, Daniel R Gomez, Bruce D Minsky, Claus Rödel, Emmanouil Fokas,

Landmark investigation two decades ago demonstrated sex-based disparities among participants in cancer cooperative group trials. Although federal efforts have aimed to improve representation of female patients in government-sponsored research, less is known about sex disparities in the broader landscape of modern oncologic randomized controlled trials. Using ClinicalTrials.gov, we identified randomized ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):211-213]

Cited: 0 times

View full text PDF listing >>



Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.

Sarah L Kerns, Laura Fachal, Leila Dorling, Gillian C Barnett, Andrea Baran, Derick R Peterson, Michelle Hollenberg, Ke Hao, Antonio Di Narzo, Mehmet Eren Ahsen, Gaurav Pandey, Søren M Bentzen, Michelle Janelsins, Rebecca M Elliott, Paul D P Pharoah, Neil G Burnet, David P Dearnaley, Sarah L Gulliford, Emma Hall, Matthew R Sydes, Miguel E Aguado-Barrera, Antonio Gómez-Caamaño, Ana M Carballo, Paula Peleteiro, Ramón Lobato-Busto, Richard Stock, Nelson N Stone, Harry Ostrer, Nawaid Usmani, Sandeep Singhal, Hiroshi Tsuji, Takashi Imai, Shiro Saito, Rosalind Eeles, Kim DeRuyck, Matthew Parliament, Alison M Dunning, Ana Vega, Barry S Rosenstein, Catharine M L West,

BACKGROUND:A total of 10%-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies. METHODS:We conducted an individual patient data meta-analysis of six genome-wide association studies (n = 3871) in men of European ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):179-190]

Cited: 1 time

View full text PDF listing >>



Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.

Janet R Vos, Ingrid E Fakkert, Joanne A de Hullu, Anne M van Altena, Aisha S Sie, Hicham Ouchene, Riki W Willems, Iris D Nagtegaal, Marjolijn C J Jongmans, Arjen R Mensenkamp, Gwendolyn H Woldringh, Johan Bulten, Edward M Leter, C Marleen Kets, Michiel Simons, Marjolijn J L Ligtenberg, Nicoline Hoogerbrugge, ,

BACKGROUND:Women with epithelial ovarian cancer (OC) have a higher chance to benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy if their tumor has a somatic or hereditary BRCA1/2 pathogenic variant. Current guidelines advise BRCA1/2 genetic predisposition testing for all OC patients, though this does not detect somatic variants. We assessed ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2020, 112(2):161-169]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.3144 s